Komplementarno serološko i molekularno testiranje krvno-prenosivih patogena i procena sociodemografskih karakteristika kod korisnika intravenskih droga na supstitucionoj terapiji u Šumadijskom okrugu Srbije

  • Nemanja Borovčanin Military Medical Academy, Institute for Transfusiology and Hemobiology, Belgrade, Serbia
  • Elizabeta Ristanović Military Medical Academy, Institute for Microbiology, Belgrade, Serbia
  • Milena Todorović Clinical Center of Serbia, Clinic for Hematology, Belgrade, Serbia
  • Milica Borovčanin University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
  • Mirjana Jovanović University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
  • Bela Balint Military Medical Academy, Institute for Transfusiology and Hemobiology, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP170814129B
Ključne reči: poremećaji izazvani opioidima;, krvno-prenosivi patogeni;, metadon;, hepatitis b, virus;, hepacivirus;, hiv;, serologija;, demografija;, srbija.

Sažetak


Uvod/Cilj. Korisnici intravenskih droga predstavljaju viso­korizičnu grupu zbog međusobnih infekcija krvno pre­nosivim bolestima, vertikalne transmisije patogena, kao i zbog mogućnosti da budu potencijalni donori krvi/pro­dukata plazme (naročito kao plaćeni donori). Cilj našeg istraživanja bio je utvrđivanje demografsko-sociološkog profila 99 opijatnih zavisnika Šumadijskog okruga lečenih u Kliničkom centru Kragujevac supstitucio­nom terapijom metadonom i buprenorfinom, kao i određivanje prevalencije infekcija krvno prenosivim bole­stima: virusom hepatitisa B (HBV), virusom hepatitisa C (HCV) i virusom stečene imunodeficijencije (HIV). Me­tode. Ispitanici su odgovarali na pitanja iz Pompidu upit­nika i podaci iz ovog upitnika korišćeni su za analizu osnov­nih socio-demografskih karakteristika. Svi uzorci su prvo te­stirani ELISA (Enzyme-Linked ImmunoSorbent Assay) i CIA (Chemiluminescent Immuno-Assay) metodom, a zatim PCR-om (Polymerase Chain Reaction). Rezultati. Najveći broj ispitanika bilo je muškog pola (81,8%), starosti 32 (19–57) godine, 99% ispitanika živelo je u gradu, nezaposlenih je bilo 58,6%, sa završenom srednjom školom 67,7%, a korisnika neade­kvatne primene igala bilo je 34,3%. Netestiranih na HBV bilo je 39,4%, na HCV 36,4%, HIV 28,3% a samo njih 4 (4%) primilo je vakcinu protiv HBV. Što se tiče analiza na prisusustvo HBV infekcije, ELISA/CIA i PCR negativnih je bilo 66, HBV ELISA/CIA i PCR pozitivnih bilo je 19, HBV ELISA/CIA-nega­tiv­nih/PCR-pozitivnih 12 i HBV ELISA/CIA-pozitiv­nih/PCR-negativnih 2 ispitanika. Testi­ranje na HCV infekciju je pokazalo sledeće: ELISA/CIA i PCR negativnih ispitanika je bilo 15, HCV ELISA/CIA i PCR pozitivnih bilo je 58, HCV ELISA/CIA-negativ­nih/PCR-pozitivnih 11, a HCV ELISA/CIA-pozitiv­nih/PCR-negativnih 15. Svi ispitanici bili su negativni na HIV (ELISA/CIA i PCR testiranje), kao i na patogene oportunističkih infekcija (Cryptococcus neoformans; Pneumocystis carinii; PCR testiranje) i na prisustvo virusa zapadnog Nila (West Nile Virus; PCR testiranje). Jedan ispitanik bio je po­zitivan na sifilis (ELISA testiranje). Zaključak. Naši rezul­tati pokazali su da je pozitivnost na prisustvo patogena krvno prenosivih bolesti HBV i HCV visoka u ispitivanoj grupi korisnika intravenskih droga i iznosi 33,4% i 84,8%, respektivno. Preporuka bi bila da oni budu periodično testi­rani na prisustvo HBV, HCV i HIV infekcije komplemen­tarnim ELISA/CIA testovima, kao i PCR testovima, obzi­rom na izvestan stepen diskrepance u dobijenim rezultatima serološkog i molekularnog testiranja.

Biografija autora

Nemanja Borovčanin, Military Medical Academy, Institute for Transfusiology and Hemobiology, Belgrade, Serbia

Institute of Transfusiology and Hemobiology

Reference

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9(7): e103345.

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsycho-pharmacol 2011; 21(9): 655–79.

Wales N. A review of viral hepatitis in injecting drug users and assessment of priorities for future activates. Geneva: WHO; 2009.

Gyarmathy VA, Neaigus A, Li N, Ujhelyi E, Caplinskiene I, Caplinskas S, et al. Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human im-munodeficiency virus. Scand J Infect Dis 2011; 43(1): 32–42.

Ruan Y, Liang S, Zhu J, Li X, Pan SW, Liu Q, et al. Evaluation of harm reduction programs on seroincidence of HIV, hepati-tis B and C, and syphilis among intravenous drug users in southwest China. Sex Transm Dis 2013; 40(4): 323–8.

Djukić Dejanović S, Borovčanin M. Principes of treatment of opi-ate dependents in Serbia. In: Djukić Dejanović S, Nastasić P, edi-tors. Dependence diseases: Modern achivements in Preven-tion, treatment and rehabilitation Beograd: ECPD; 2015. p. 10–2. (Serbian)

Тrkuljić M, Borovčanin N, Vučetić D, Jovičić D. Transmissible dis-eases – Etiopathogenesis, markers testing, inactivation of pathogenes. In: Balint B, Trkuljić M, Todorović M, editors. Basic principles of chemotherapy. Beograd: Čigoja štampa; 2010. p. 421–505. (Serbian)

Vučetić D, Kecman G, Ilić V, Balint B. Blood donors' positivity for transfusion-transmissible infections: the Serbian Military Medical Academy experience. Blood Transfus 2015; 13(4): 569–75.

Simon R, Donmall M, Hartnoll R, Kokkevi A, Ouwehand AW, Stauffacher M, et al. The EMCDDA/Pompidou Group treat-ment demand indicator protocol: a European core item set for treatment monitoring and reporting. Eur Addict Res 1999; 5(4): 197–207.

Allain PJ. Emerging Viruses in Transfusion. In: Barbara JA, Regan FA, Contreras MC, editors. Transfusion Microbiology. New York: Cambridge University Press; 2008. p. 75–86.

Honarvar B, Odoomi N, Moghadami M, Kazerooni PA, Has-sanabadi A, Dolatabadi PZ, et al. Blood-Borne Hepatitis in Opiate Users in Iran: A Poor Outlook and Urgent Need to Change Nationwide Screening Policy. PLoS One 2013; 8(12): e82230.

Zamania S, Radfarb R, Nematollahic P, Fadaiec R, Meshkatic M, Mortazavia S, et al. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 2010; 21(6): 493–500.

Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, et al. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. Ann Ist Super Sanità 2010; 46(1): 59–65.

Goulao J, Götz W. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2012: The state of the drug problem in Europe. Lisbon: EMCDDA; 2012.

Amon JJ. Hepatitis in drug users: time for attention, time for action. Lancet 2011; 378 (9791): 543–4.

Balint B, Vucetic D, Todorovic-Balint M, Borovcanin N, Jovanovic-Cupic S, Mandusic V. Safety improving by complementary sero-logical and molecular testing combined with pathogen reduc-tion of the donated blood in window period (Letter). Transfus Apher Sci 2013; 49(1): 103–4.

Busch M, Glynn S, Stramer S, Orland J, Murphy E, Wright D, et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV- seropositive blood donors. Transfusion 2006; 46(3): 469–75.

Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfu-sion 2004; 44(9): 1332–9.

Objavljeno
2021/05/20
Broj časopisa
Vol. 76 Br. 6 (2019): Vojnosanit pregl
Rubrika
Originalni članak